Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | – | -$18,255 | -$22,644 | -$22,290 |
| Dep. & Amort. | – | $1,210 | $1,203 | $889 |
| Deferred Tax | – | $0 | $0 | $0 |
| Stock-Based Comp. | – | $4,177 | $4,688 | $5,666 |
| Change in WC | – | $32,302 | $2,110 | $113 |
| Other Non-Cash | – | -$1,928 | $1,155 | -$1,179 |
| Operating Cash Flow | – | $17,506 | -$13,488 | -$16,801 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | – | -$155 | -$2,538 | -$8,745 |
| Net Acquisitions | – | $0 | $0 | $0 |
| Inv. Purchases | – | -$85,992 | -$55,016 | $0 |
| Inv. Sales/Matur. | – | $59,664 | $53,185 | $77,648 |
| Other Inv. Act. | – | $0 | $0 | $0 |
| Investing Cash Flow | – | -$26,483 | -$4,369 | $68,903 |
| Financing Activities | – | – | – | – |
| Debt Repay. | – | $0 | $0 | -$4,943 |
| Stock Issued | – | $0 | $0 | $0 |
| Stock Repurch. | – | $0 | $0 | $0 |
| Dividends Paid | – | $0 | $0 | $0 |
| Other Fin. Act. | – | -$6,424 | -$6,887 | -$43 |
| Financing Cash Flow | – | -$6,424 | -$6,887 | -$4,986 |
| Forex Effect | – | $0 | $0 | $0 |
| Net Chg. in Cash | – | -$15,401 | -$24,744 | $47,116 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | – | $63,573 | $88,317 | $41,201 |
| End Cash | – | $48,172 | $63,573 | $88,317 |
| Free Cash Flow | – | $17,351 | -$16,026 | -$25,546 |